We organise an event on clinical PET in Alzheimer’s in the framework of the EANM 2025

The Barcelonaβeta Brain Research Center (BBRC), the research center of the Pasqual Maragall Foundation, hosted a satellite event during EANM 2025 titled “Clinical Use of PET in Alzheimer’s Disease: Challenges and Opportunities with New Treatments.” Held on 7 October 2025, the session gathered 50 clinicians and researchers to discuss how amyloid, FDG and tau PET can inform diagnosis, prognosis and treatment monitoring in the era of disease-modifying therapies.

The session brought together two invited speakers, Dr. Javier Arbizu and Dr. Valentina Garibotto, who offered complementary clinical and research perspectives on PET in Alzheimer’s disease. 

Javier Arbizu (Director of the Nuclear Medicine Service of the Clínica Universidad de Navarra) reviewed the evolving clinical roles of amyloid and FDG PET, emphasizing appropriate-use criteria, interpretation pitfalls, and how PET may complement biomarkers when considering anti-amyloid therapies. Valentina Garibotto (Head of the Division of Nuclear Medicine and Molecular imaging – HUG, Université de Genève) presented real-world insights on tau PET in memory clinic populations, highlighting patterns of tracer uptake across clinical stages and its utility for differential diagnosis and patient stratification.

The event closed with an open discussion on integrating PET with fluid biomarkers and cognitive assessment, harmonizing reporting across centers, and designing pragmatic pathways for therapy follow-up. Organized by Dr. Gemma Salvadó and Dr. David Vállez, the session reflects BBRC’s commitment to accelerating evidence into practice and fostering multicenter alignment in neuroimaging.